A Phase 2 interventional study of AZD9977 and Dapagliflozin in Heart Failure and Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 156 sites in 22 countries. Open to participants aged 21 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-11-19.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.
Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 20th largest by enrollment, is one of 10 that started in 2021, is one of 9 in phase 2, and was the 17th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 12+
Yale University · Sites in United States
Ages 18–85 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 40+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 21 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 20 · Phase 4 22
First in 2015; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 100 across the 59 interventional studies. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
64 studies in Heart Failure by AstraZeneca: 6 open now, 8 under way, 3 of them phase 3. Of 54 finished, 14 (26%) have results posted.
Among the 64 studies in Heart Failure by AstraZeneca, this one is the 22nd largest by enrollment of the 39 interventional ones that give a count, is one of 9 that started in 2021, is one of 8 in phase 2, and was the 35th registered.
AstraZeneca’s Heart Failure studies by the year they started, since 1999.
4 of the studies testing dapagliflozin in Heart Failure that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06304857Phase 34th Military Clinical Hospital with Polyclinic, PolandCardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL | 2026-12-31 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing dapagliflozin in Heart Failure, from their registry updates:
Among AstraZeneca’s 64 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF [below 60%]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR [between ≥ 20 and ≤ 60 mL/min/1.73 m\^2, with at least 20% of participants with eGFR ≥ 20 to \<30 mL/min/1.73\^2 and a maximum of 35% of participants with eGFR ≥ 45 mL/min/1.73 m\^2]).
After screening, eligible participants will undergo a run-in period where all participants receive dapagliflozin for up to 7 weeks depending on pre-study use of SGLT2i or not. At the end of the run-in period, eligible participants will be randomly assigned with a 1:1:1:1 ratio to receive once daily administration of one of the following 4 study treatments group for 12 weeks. To ensure blinding, the study treatment will be administered in the form of 3 oral capsules of AZD9977 or placebo and 1 oral tablet or dapagliflozin.
Participants will be randomized to one of the above treatment group, according to type 2 diabetes mellitus [T2DM (yes/no)] and eGFR (≥ 20 to \<30 mL/min/1.73\^2; or ≥ 30 to \< 45 mL/min/1.73\^2; or ≥45 mL/min/1.73\^2).
The total duration of participation will be approximately 22 to 24weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are included in the study if any of the following criteria apply:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.
Drug: AZD9977 · Drug: Dapagliflozin
Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.
Drug: AZD9977 · Drug: Dapagliflozin
Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.
Drug: AZD9977 · Drug: Dapagliflozin
Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
Drug: Dapagliflozin
Participants will receive AZD9977 as per the arms they are randomized.
Participants will receive dapagliflozin as per the arms they are randomized.
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12
The effect of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone on UACR assessed. Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as 10 x urine albumin (mg per deciliter \[mg/dL\])/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants only descriptive statistics are shown for those two arms without formal comparison.
Time frame: Baseline (Day 1) to Week 12
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at 12 Weeks to Assess Dose-Response Relationship
The dose-response relationship of dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on UACR was assessed. Urine samples were collected for the analysis of UACR. UACR (mg/g) was calculated as 10 x urine albumin (mg/dL)/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants, only descriptive statistics was shown for those two arms without formal comparison.
Time frame: Baseline (Day 1) to Week 12
Number of Participants With Adverse Events (AEs)
The safety and tolerability of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo was assessed.
Time frame: From baseline (Day 1) until Day 113
Change From Baseline in Serum Potassium (K+)
Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.
Time frame: Baseline (Day 1) and Week 12
Absolute Value of Serum Potassium Over Time
Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed.
Time frame: Baseline (Day 1) and Week 12
Absolute Value of eGFR Over Time
Effect of all doses of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed
Time frame: Baseline (Day 1) to Week 12
The study was conducted between 26-January-2021 (first subject first visit) to 22-September-2023 (last subject last visit).
| Milestone | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Started | 35 | 33 | 36 | 7 | 35 | 7 |
| Completed | 33 | 25 | 27 | 6 | 29 | 6 |
| Not completed | 2 | 8 | 9 | 1 | 6 | 1 |
| Withdrew: Subjects randomised, not treated, protocol deviation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subjects randomised, not treated, withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 4 | 3 | 1 | 1 | 1 |
| Withdrew: Withdrawal of consent | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol-specified withdrawal criterion met | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participants discontinued study treatment due to other reasons | 0 | 2 | 2 | 0 | 1 | 0 |
The effect of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone on UACR assessed. Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as 10 x urine albumin (mg per deciliter \[mg/dL\])/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants only descriptive statistics are shown for those two arms without formal comparison.
| Percent change from baseline | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 | -56.391 (-71.528 to -33.207) | -42.085 (-64.174 to -6.376) | -58.047 (-73.560 to -33.430) | -45.01 (NA to NA) | -34.318 (-58.204 to 3.220) | 230.32 (NA to NA) |
The dose-response relationship of dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on UACR was assessed. Urine samples were collected for the analysis of UACR. UACR (mg/g) was calculated as 10 x urine albumin (mg/dL)/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants, only descriptive statistics was shown for those two arms without formal comparison.
| Percent change from baseline | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at 12 Weeks to Assess Dose-Response Relationship | -56.391 (-71.528 to -33.207) | -42.085 (-64.174 to -6.376) | -58.047 (-73.560 to -33.430) | -45.01 (NA to NA) | -34.318 (-58.204 to 3.220) | 230.32 (NA to NA) |
The safety and tolerability of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo was assessed.
| Participants | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Any AE | 9 | 12 | 18 | 5 | 14 | 3 |
| Any SAE | 1 | 3 | 2 | 0 | 4 | 2 |
| Any SAE with outcome death | 0 | 2 | 0 | 0 | 1 | 0 |
| Any AE leading to discontinuation of IP | 0 | 4 | 3 | 1 | 1 | 1 |
| Any AE leading to withdrawal from study | 0 | 5 | 2 | 0 | 1 | 0 |
| Any AE leading to dose interruption | 1 | 1 | 1 | 0 | 3 | 1 |
Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.
| millimoles per liter (mmol/L) | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in Serum Potassium (K+) | 0.056 (-0.106 to 0.219) | 0.003 (-0.184 to 0.190) | 0.109 (-0.061 to 0.279) | 0.55 (NA to NA) | 0.040 (-0.129 to 0.209) | 0.03 (NA to NA) |
Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.
| mmol/L | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Baseline | 4.60 ± 0.38 | 4.44 ± 0.61 | 4.46 ± 0.44 | 4.50 ± 0.38 | 4.60 ± 0.66 | 4.50 ± 0.28 |
| Week 12 | 4.62 ± 0.50 | 4.53 ± 0.43 | 4.63 ± 0.43 | 5.00 ± 0.61 | 4.64 ± 0.40 | 4.33 ± 0.32 |
Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed.
| mL/min/1.73 m^2 | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) | -1.432 (-4.305 to 1.441) | -1.160 (-4.351 to 2.030) | -5.307 (-8.295 to -2.320) | -0.923 (NA to NA) | -3.498 (-6.528 to -0.469) | 6.880 (NA to NA) |
Effect of all doses of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed
| mL/min/1.73 m^2 | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Baseline | 41.341 ± 12.902 | 38.586 ± 10.155 | 43.663 ± 16.168 | 36.874 ± 12.626 | 41.895 ± 12.791 | 40.288 ± 15.176 |
| Week 12 | 41.219 ± 15.112 | 39.429 ± 8.998 | 39.063 ± 13.819 | 34.075 ± 21.071 | 37.973 ± 11.571 | 48.920 ± 21.111 |
Collected over From baseline (Day 1) until Day 113. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD9977 15 mg + Dapagliflozin 10 mg | 0/33 (0%) | 1/33 (3%) | 1/33 (3%) |
| AZD9977 50 mg + Dapagliflozin 10 mg | 2/31 (6.5%) | 3/31 (9.7%) | 4/31 (12.9%) |
| AZD9977 150 mg + Dapagliflozin 10 mg | 0/34 (0%) | 2/34 (5.9%) | 13/34 (38.2%) |
| AZD9977 150 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Dapagliflozin 10 mg | 1/33 (3%) | 4/33 (12.1%) | 7/33 (21.2%) |
| Placebo | 0/5 (0%) | 2/5 (40%) | 2/5 (40%) |
| Event | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/33 | 1/31 | 0/34 | 0/6 | 0/33 | 1/5 |
| Cardiac failureCardiac disorders | 0/33 | 1/31 | 1/34 | 0/6 | 0/33 | 1/5 |
| Left ventricular failureCardiac disorders | 0/33 | 1/31 | 0/34 | 0/6 | 0/33 | 0/5 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/33 | 1/31 | 0/34 | 0/6 | 0/33 | 0/5 |
| Cardiac failure congestiveCardiac disorders | 0/33 | 0/31 | 0/34 | 0/6 | 1/33 | 0/5 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/33 | 0/31 | 0/34 | 0/6 | 1/33 | 0/5 |
| Peripheral swellingGeneral disorders | 0/33 | 0/31 | 0/34 | 0/6 | 1/33 | 0/5 |
| Sudden cardiac deathGeneral disorders | 0/33 | 0/31 | 0/34 | 0/6 | 1/33 | 0/5 |
| Hepatic enzyme increasedInvestigations | 1/33 | 0/31 | 0/34 | 0/6 | 0/33 | 0/5 |
| Transient ischaemic attackNervous system disorders | 0/33 | 0/31 | 1/34 | 0/6 | 0/33 | 0/5 |
| Event | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/33 | 0/31 | 2/34 | 0/6 | 0/33 | 1/5 |
| SyncopeVascular disorders | 0/33 | 0/31 | 1/34 | 0/6 | 0/33 | 1/5 |
| ColitisGastrointestinal disorders | 0/33 | 0/31 | 0/34 | 0/6 | 0/33 | 1/5 |
| HyperthyroidismEndocrine disorders | 0/33 | 0/31 | 0/34 | 0/6 | 0/33 | 1/5 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/33 | 0/31 | 0/34 | 0/6 | 0/33 | 1/5 |
| Diabetes mellitusEndocrine disorders | 0/33 | 0/31 | 0/34 | 0/6 | 0/33 | 1/5 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/33 | 1/31 | 2/34 | 1/6 | 3/33 | 0/5 |
| Chronic kidney diseaseRenal and urinary disorders | 1/33 | 1/31 | 2/34 | 1/6 | 1/33 | 0/5 |
| HypotensionVascular disorders | 0/33 | 0/31 | 0/34 | 1/6 | 0/33 | 0/5 |
| HeadacheNervous system disorders | 0/33 | 0/31 | 0/34 | 1/6 | 0/33 | 0/5 |
Total 153 participants were randomized but 9 participants were excluded from full analysis set (FAS) due to good clinical practice (GCP) misconduct at site. Hence, 144 participants were included in FAS. FAS included all participants who were randomized and either received or did not receive any study intervention.
| Age, Continuous(Years) | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 70.9 ± 7.1 | 72.4 ± 8.4 | 73.7 ± 8.1 | 77.0 ± 8.7 | 72.2 ± 9.4 | 77.2 ± 5.8 | 72.7 ± 8.2 |
| Sex: Female, Male(Participants) | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 11 | 5 | 8 | 1 | 10 | 1 | 36 |
| Male | 23 | 26 | 27 | 5 | 23 | 4 | 108 |
| Race/Ethnicity, Customized(Participants) | AZD9977 15 mg + Dapagliflozin 10 mg | AZD9977 50 mg + Dapagliflozin 10 mg | AZD9977 150 mg + Dapagliflozin 10 mg | AZD9977 150 mg | Dapagliflozin 10 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Asian | 4 | 3 | 7 | 0 | 3 | 0 | 17 |
| Black or African American | 0 | 1 | 1 | 0 | 2 | 1 | 5 |
| White | 30 | 27 | 27 | 6 | 28 | 4 | 122 |
Showing the first 100 of 156 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jan 2021 to primary completion in Sep 2023, 31 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 31 months is above that.
Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin